Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Researchers discover new genetic risk factor for schizophrenia, bipolar disorder

Investigators at The Feinstein Institute for Medical Research have discovered a new genetic risk factor for schizophrenia and bipolar disorder called NDST3. The findings are published online in Nature Communications.

20 Nov 2013

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.

18 Nov 2013

Mayo Clinic Cardio-Rheumatology Clinic created for catching heart disease early in arthritis patients

Patients with rheumatoid arthritis, lupus and other chronic forms of inflammatory arthritis can face life-threatening complications, and heart disease tops the list. People with such rheumatic diseases are twice as likely as the average person to develop heart problems.

15 Nov 2013

Cells sticking molecule over-produced in rheumatoid arthritis and cancers

A molecule that helps cells stick together is significantly over-produced in two very different diseases - rheumatoid arthritis and a variety of cancers, including breast and brain tumors, concludes a new study. The scientists who made the discovery also found candidate drugs to inhibit the molecule, cadherin-11, one of which is already in a clinical trial.

14 Nov 2013

Skeletal problems now added to list of diabetes complications

The list of complications from type 2 diabetes is long: vascular and heart disease, eye problems, nerve damage, kidney disease, hearing problems and Alzheimer's disease. Physicians have long thought of osteoporosis as another outcome. Based on a Mayo Clinic study published in the Journal of Bone and Mineral Research, that's confirmed: You can definitely add skeletal problems to that list.

14 Nov 2013

Researchers identify specific IRE1a inhibitor for rheumatoid arthritis treatment

Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.

13 Nov 2013

Treatment with rheumatoid arthritis drug saved transplanted kidney and achieved remission

A drug approved for the treatment of rheumatoid arthritis may also turn out to be the first targeted therapy for one of the most common forms of kidney disease, a condition that almost inevitably leads to kidney failure.

11 Nov 2013

TGen-led study reveals viable target to prevent spread of brain cancer

A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.

11 Nov 2013

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

Researchers have linked a species of intestinal bacteria known as Prevotella copri to the onset of rheumatoid arthritis, the first demonstration in humans that the chronic inflammatory joint disease may be mediated in part by specific intestinal bacteria.

6 Nov 2013

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute.

4 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

Scientists unravel the major cause of protein citrullination in rheumatoid arthritis

Experiments by scientists at Johns Hopkins and in Boston have unraveled two biological mechanisms as the major cause of protein citrullination in rheumatoid arthritis. Protein citrullination is suspected of sparking the immune system and driving the cascade of events leading to the disease.

31 Oct 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

Bending ethical norms to serve patients' interests

A survey among rheumatologists finds many face moral dilemmas when trying to do what's best for their patients in the current health care environment.

29 Oct 2013

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

People with a type of arthritis affecting the skin and joints respond significantly better to early, aggressive drug treatment compared to standard care, according to preliminary results presented by a University of Leeds lecturer to a major US conference.

29 Oct 2013

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.

28 Oct 2013

Socially isolated individuals more likely to experience ongoing pain following THR surgery

Researchers at Hospital for Special Surgery set out to test this hypothesis. They found that people who lacked good social ties were much more likely to experience serious, ongoing pain following total hip replacement surgery two or more years after the procedure.

28 Oct 2013

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Starting with a combination of three traditional disease-modifying antirheumatic drugs (called DMARDs) for treating early rheumatoid arthritis is more cost-effective long term, with comparable benefits, than using either an immediate or step-up approach with anti-tumor necrosis factor (called Anti-TNFs) drugs and methotrexate, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Young, middle-aged fibromyalgia patients report poorer quality of life than older patients

It may seem counterintuitive, but young and middle-aged fibromyalgia patients report worse symptoms and poorer quality of life than older patients, a Mayo Clinic study shows.

28 Oct 2013

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Researchers discover new genetic risk factor for schizophrenia, bipolar disorder

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Mayo Clinic Cardio-Rheumatology Clinic created for catching heart disease early in arthritis patients

Cells sticking molecule over-produced in rheumatoid arthritis and cancers

Skeletal problems now added to list of diabetes complications

Researchers identify specific IRE1a inhibitor for rheumatoid arthritis treatment

Treatment with rheumatoid arthritis drug saved transplanted kidney and achieved remission

TGen-led study reveals viable target to prevent spread of brain cancer

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Scientists unravel the major cause of protein citrullination in rheumatoid arthritis

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

Bending ethical norms to serve patients' interests

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Socially isolated individuals more likely to experience ongoing pain following THR surgery

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Young, middle-aged fibromyalgia patients report poorer quality of life than older patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in